Trevi Therapeutics, Inc.
TRVIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary. At a $1.92B market cap, Trevi Therapeutics, Inc. ranks as a small-cap company within healthcare. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Market Cap
$1.92B
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
-24.20
EPS (TTM)
$-0.32
EPS (Fwd)
$-0.56
ROE
-33.6%
ROA
-23.0%
Cash
$171.8M
Total Debt
$682,000
Free CF
-$28.5M
52W Change
105.2%
Annual Financials
Cash vs Debt
With $171.8M in cash and $682K in debt, TRVI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$28.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -33.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TRVI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.